{
  "symbol": "RPID",
  "company_name": "Rapid Micro Biosystems Inc Cl A",
  "ir_website": "https://investors.rapidmicrobio.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference",
          "url": "https://investors.rapidmicrobio.com/news-releases/news-release-details/rapid-micro-biosystems-participate-stifel-2024-healthcare",
          "content": "This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.\n\nIf you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.\n\n[ Accept ](javascript:void\\(0\\);) [Decline](javascript:void\\(0\\);)\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![logo](/sites/g/files/knoqqb65751/themes/site/nir_pid4252/dist/images/rmb_logo_4c.png) ](https://www.rapidmicrobio.com/)\n\n## Investor Relations\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News & Events](/news-and-events/news-releases)\n    * [News Releases](/news-and-events/news-releases)\n    * [Events](/news-and-events/events)\n    * [Presentations](/news-and-events/presentations)\n  * [Stock Information](/stock-information/stock-quote-chart)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [Corporate Governance](/corporate-governance/documents-and-charters)\n    * [Documents & Charters](/corporate-governance/documents-and-charters)\n    * [Board of Directors](/corporate-governance/board-of-directors)\n    * [Leadership](https://investors.rapidmicrobio.com/corporate-governance/management)\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Code of Business Conduct and Compliance Hotline](/code-business-conduct-and-ethics-0)\n  * [Financials & Filings](/financials-and-filings/sec-filings)\n    * [SEC Filings](/financials-and-filings/sec-filings)\n  * [IR Resources](/ir-resources/faqs)\n    * [FAQs](/ir-resources/faqs)\n    * [Email Alerts](/ir-resources/email-alerts)\n    * [Contact IR](/ir-resources/contact-ir)\n\n\n\n#  News Release Details \n\n## \n\nRapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference\n\n11/08/2024 \n\nLEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference.\n\nRob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer session with the host analyst on Monday, November 18, 2024 at 11:30 a.m. Eastern Time.\n\nA live webcast will be available on the Rapid Micro Biosystems investor relations website at [https://investors.rapidmicrobio.com/](https://www.globenewswire.com/Tracker?data=yq6KkjlSndSCDRvRqJOawGRUqU1TKAc0lBLWD7klOKGDLZhMx6pnNSssOTACvyBeGtn-O5ydToOUN0w3tWtkrGviL2aYo-67hTPLYS8PfVhtXQo7_I3SC5zzizsrzdJu3qPi1kORW5BXVFBW-ip6XBrLRGbAQ0dQStXmKH83Buk5GfQpP1wwA9OW1hDXiasJf1q5DSWXqWo5eJpLYiAbAH1y_wXQLV37tZwFGkMt62RGsEmSggV1yo7OtAw0RVzH-80J3ouu1em9AIUwDg5-yWC8ShJYl3OdAQKLO6fA0WgH_qozYeehfs2dmgqEpIV1) and can be accessed [here](https://www.globenewswire.com/Tracker?data=JiZnladK-YvTn5OK-ASnwZM_0-9hluikRvDMxWV_jeTnaPy3aOlMygYw-3qrlPgGwzS-n60X8awnfspjhPRCKNLXAvZNaMjsktpJxS2FM_42c5p8Q3op4_qQ3FizjfPsnZx5lHTs855jmv-mys5PsQMNTBmtFqPQ8l91CQsqNC8ubWbZrO_uoygLolrVL5Z6Zsz4zzPq9brEahkOYmyryZaHrjaW4YtntipOsnNH4tbti4zUPkteGCzNa8IKXBGkwt9sZhbf6xZOZpciXdjFeg==). The webcast will be archived and available for replay after the event.\n\n**About Rapid Micro Biosystems**\n\nRapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit [www.rapidmicrobio.com](https://www.globenewswire.com/Tracker?data=du5ctwROG8pvqe9STgLClGQyIyqR111U2tbTqegDOisawUOU2YsC_YwkH6OK1MStR4bWkMtA9GF7wXCh2qQ_v2xLIaFl7TImJHEdOEOgZMU=) or follow the Company on Twitter at [@rapidmicrobio](https://www.globenewswire.com/Tracker?data=xVmNW3y2XlVkbRe5SsGmd3M6YpB-4VpYScsj2Pk5Yhx5kkpQVGjefWADCJdrUl_ccOxxzjjSbe6vWP8BXfCFNuqr0t9nMsLOIBGIoOjCmXGlUKna-oedRg85T1pq-Zfm2LPM7vb5jA-G1XQtv5qcWWIe_1KI2h15EYFNvHy3SlD2gCDEGn6CobzmeNAVFbihIc6r1pHwijoEUQASrsD55ri-WTODHoY-r-zw_mqd00XoG6k9O6p8n-Bk2wHzeQjdzazKmR9fwDd23m-4Vu2jSI_8EcuBJwKMl6qx5kDprwjAzXfrURfyinZCss_do88gISrCtJ7_AD9TExHBd-KXpwnDPGpdmPxn3pxKGf49ab9hGrhHeG-zXasBAQ8xyTiAJSBmlbsMYbBTBO6AHM3jL1_GpFBViLUbZAqcAQ5XOgP1hJr6B5Z4oswnPjy-rJR8rvaiwgzk9k1ndSz1MSNQCQ==) or on [LinkedIn](https://www.globenewswire.com/Tracker?data=pcDf8vtkNae3HceteKukMZPYpJlCwlX-jqFQBxSh7CPL4STCLWL_BIpy4926Q1rnWPQ2niFJ8RStoLiazNhz9l506cPIxAaSbuwtFTo_HoycJE9OHX5qIbaz7mpzdjyTyi2F93xdGUU9E07Hwm1gCz66350IwcTz6S0ZnME-3lO3EKq9x-RgbDizIFqys4Xtzz3t_4xqUhK9cXfuKmVcC1Wd-tp5J5HxJRjnVn6eOqPtgZajwTaltuHAYy6zOEIS3FitUk2vODZLNi-EJ4VulEOAr4UKiSNr0CdB8KKAatYVVB7FG8FWfOxtNAbI-qNz65xavFxcOQsExi-bKOTgxGpsLF1xtgNI67RMnDD9Ifyl1B7A_ysR0M4v03aYMDl3-aotNdT2pUH0HPPXOWFcaeEfUm_czWCr_qapS8rbYjzl-4rWA1mzeH3nURJI-qealO6OJry-Z_C6dSRCiOyvj2MITAk7IbrUDVrkqrQph9g=).\n\n![](https://ml.globenewswire.com/media/ZjEwYTJlMzUtZGUyMS00MzE0LTk2YTYtMDQ4ZWNkNDU0MWM0LTEwMzAxMzQ=/tiny/Rapid-Micro-Biosystems-Inc-.png)\n\nInvestor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com\n\nRequest Email Alerts\n\n[](#)\n"
        },
        {
          "title": "Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results",
          "url": "https://investors.rapidmicrobio.com/news-releases/news-release-details/rapid-micro-biosystems-reports-third-quarter-2024-financial",
          "content": "This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.\n\nIf you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.\n\n[ Accept ](javascript:void\\(0\\);) [Decline](javascript:void\\(0\\);)\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![logo](/sites/g/files/knoqqb65751/themes/site/nir_pid4252/dist/images/rmb_logo_4c.png) ](https://www.rapidmicrobio.com/)\n\n## Investor Relations\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News & Events](/news-and-events/news-releases)\n    * [News Releases](/news-and-events/news-releases)\n    * [Events](/news-and-events/events)\n    * [Presentations](/news-and-events/presentations)\n  * [Stock Information](/stock-information/stock-quote-chart)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [Corporate Governance](/corporate-governance/documents-and-charters)\n    * [Documents & Charters](/corporate-governance/documents-and-charters)\n    * [Board of Directors](/corporate-governance/board-of-directors)\n    * [Leadership](https://investors.rapidmicrobio.com/corporate-governance/management)\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Code of Business Conduct and Compliance Hotline](/code-business-conduct-and-ethics-0)\n  * [Financials & Filings](/financials-and-filings/sec-filings)\n    * [SEC Filings](/financials-and-filings/sec-filings)\n  * [IR Resources](/ir-resources/faqs)\n    * [FAQs](/ir-resources/faqs)\n    * [Email Alerts](/ir-resources/email-alerts)\n    * [Contact IR](/ir-resources/contact-ir)\n\n\n\n#  News Release Details \n\n## \n\nRapid Micro Biosystems Reports Third Quarter 2024 Financial Results\n\n11/01/2024 \n\n  * **_Reports record third quarter 2024 revenue of_**** _$7.6 million_**** _, representing growth of_**** _24%_****_compared to the third quarter of 2023_**\n  * ** _Placed seven Growth Direct ® systems in the third quarter of 2024, marking the highest number of system placements since the third quarter of 2021_**\n    * **_Included a multi-system order at an additional site of an existing top 20 global pharma customer as part of their global Growth Direct system rollout_**\n  * **_Achieved inflection in gross margins to positive 8%, representing a significant company milestone and a 35 percentage point improvement compared to the third quarter of 2023_**\n  * ** _Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to the full year 2023_**\n\n\n\nLEXINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2024.\n\n\"We are pleased to report record quarterly revenue, accelerating system placements and a positive inflection in our gross margins in the third quarter,” said Robert Spignesi, President and CEO. \"The third quarter included a multi-system order from an existing top 20 pharma customer as they expand their Growth Direct footprint to new sites, and we remain actively engaged with several other customers planning global deployments of the Growth Direct system. We are excited about the continued momentum in the business, committed to consistent execution of our strategic priorities and confident in our path to enhancing shareholder value.\"\n\n**Third****Quarter Financial Results**\n\nTotal revenue for the third quarter of 2024 increased 24% to $7.6 million compared to $6.1 million in the third quarter of 2023. The Company placed seven new Growth Direct® systems and completed the validation of four customer systems compared to five placements and four validations in the third quarter of 2023. Product revenue increased by 25% to $5.3 million, compared to $4.2 million in the third quarter of 2023. Service revenue increased by 21% to $2.3 million, compared to $1.9 million in the third quarter of 2023. Recurring revenue increased by 8% to $3.7 million, compared to $3.4 million in the third quarter of 2023.\n\nTotal cost of revenue was $7.0 million in the third quarter of 2024, a decrease of 10% compared to $7.8 million in the third quarter of 2023. Gross margin was positive $0.6 million, or positive 8%, compared to negative $1.6 million or negative 27% in the third quarter of 2023.\n\nTotal operating expenses were $12.7 million in the third quarter of 2024, essentially flat compared to the prior year. General and administrative expenses decreased by 9%, research and development expenses increased by 16%, and sales and marketing expenses decreased by 3% compared to the third quarter of 2023.\n\nNet loss for the third quarter of 2024 was $11.3 million, compared to $13.4 million in the third quarter of 2023. Net loss per share for the third quarter of 2024 was $0.26, compared to $0.31 in the third quarter of 2023.\n\nCash, cash equivalents and short-term investments were approximately $61 million, and the Company had no debt outstanding as of September 30, 2024.\n\n**2024****Outlook**\n\nThe Company is reaffirming its full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023, and the placement of at least 20 systems.\n\n**Webcast Details**\n\nThe Company will host a conference call before the market opens today, November 1, 2024, at 9:00 a.m. ET to discuss its third quarter 2024 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.\n\n**About Rapid Micro Biosystems**\n\nRapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.\n\n**Forward-Looking Statements**\n\nThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2024 revenue and number of Growth Direct placements; the Company's ability to execute its strategic priorities and enhance shareholder value; and expected deployments of Growth Direct systems.\n\nIn some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow without requiring additional financing; the Company's ability to achieve its business objectives, including the impact of the Company's previously-announced operational efficiency plan; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.\n\n**RAPID MICRO BIOSYSTEMS, INC.**  \n---  \n**Unaudited Condensed Consolidated Statements of Operations**  \n**(in thousands, except share and per share amounts)**  \n**Three Months Ended September 30,**| **Nine Months Ended September 30,**  \n**2024**| **2023**| **2024**| **2023**  \nRevenue:  \nProduct revenue| $| 5,255| $| 4,200| $| 13,505| $| 10,693  \nService revenue| 2,349| 1,945| 6,328| 5,489  \nTotal revenue| 7,604| 6,145| 19,833| 16,182  \nCosts and operating expenses:  \nCost of product revenue| 5,314| 5,691| 15,404| 15,361  \nCost of service revenue| 1,668| 2,085| 5,519| 6,134  \nResearch and development| 3,609| 3,116| 11,195| 9,502  \nSales and marketing| 3,376| 3,498| 10,284| 10,161  \nGeneral and administrative| 5,676| 6,204| 17,121| 19,399  \nTotal costs and operating expenses| 19,643| 20,594| 59,523| 60,557  \nLoss from operations| (12,039| )| (14,449| )| (39,690| )| (44,375| )  \nOther income (expense):  \nInterest income, net| 768| 1,093| 2,589| 3,169  \nOther expense, net| (39| )| (26| )| (91| )| (66| )  \nTotal other income, net| 729| 1,067| 2,498| 3,103  \nLoss before income taxes| (11,310| )| (13,382| )| (37,192| )| (41,272| )  \nIncome tax expense| 13| 10| 31| 23  \nNet loss| $| (11,323| )| $| (13,392| )| $| (37,223| )| $| (41,295| )  \nNet loss per share — basic and diluted| $| (0.26| )| $| (0.31| )| $| (0.86| )| $| (0.96| )  \nWeighted average common shares outstanding — basic and diluted| 43,668,656| 43,080,095| 43,510,911| 42,985,184  \n  \n**RAPID MICRO BIOSYSTEMS, INC.**  \n---  \n**Unaudited Condensed Consolidated Balance Sheets**  \n**(in thousands)**  \n**September 30,****2024**| **December 31,****2023**  \n**Assets**  \nCurrent assets:  \nCash and cash equivalents| $| 22,044| $| 24,285  \nShort-term investments| 38,788| 67,768  \nAccounts receivable| 3,740| 5,532  \nInventory| 21,253| 19,961  \nPrepaid expenses and other current assets| 2,109| 2,869  \nTotal current assets| 87,934| 120,415  \nProperty and equipment, net| 11,563| 12,832  \nRight-of-use assets, net| 5,420| 6,240  \nLong-term investments| —| 2,911  \nOther long-term assets| 642| 770  \nRestricted cash| 284| 284  \nTotal assets| $| 105,843| $| 143,452  \n**Liabilities and Stockholders’ Equity**  \nCurrent liabilities:  \nAccounts payable| $| 2,329| $| 1,973  \nAccrued expenses and other current liabilities| 7,038| 9,907  \nDeferred revenue| 5,360| 5,974  \nLease liabilities, short-term| 1,193| 1,132  \nTotal current liabilities| 15,920| 18,986  \nLease liabilities, long-term| 5,261| 6,214  \nOther long-term liabilities| 289| 263  \nTotal liabilities| 21,470| 25,463  \nTotal stockholders’ equity| 84,373| 117,989  \nTotal liabilities and stockholders’ equity| $| 105,843| $| 143,452  \n  \n**RAPID MICRO BIOSYSTEMS, INC.**  \n---  \n**Unaudited Cash, Cash Equivalents and Investments**  \n**(in thousands)**  \n**September 30,****2024**| **December 31,****2023**  \nCash and cash equivalents| $| 22,044| $| 24,285  \nShort-term investments| 38,788| 67,768  \nLong-term investments| —| 2,911  \nCash, cash equivalents and investments| $| 60,832| $| 94,964  \n  \n![](https://ml.globenewswire.com/media/ZmM0YTg0NjYtOWIzYi00MWUwLWExY2UtZWNlMTNkY2Q5YWQ2LTEwMzAxMzQ=/tiny/Rapid-Micro-Biosystems-Inc-.png)\n\nInvestor Contact Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact media@rapidmicrobio.com \n\nRequest Email Alerts\n\n[](#)\n"
        },
        {
          "title": "Rapid Micro Biosystems to Announce Third Quarter 2024 Financial Results on November 1, 2024",
          "url": "https://investors.rapidmicrobio.com/news-releases/news-release-details/rapid-micro-biosystems-announce-third-quarter-2024-financial",
          "content": "This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.\n\nIf you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.\n\n[ Accept ](javascript:void\\(0\\);) [Decline](javascript:void\\(0\\);)\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![logo](/sites/g/files/knoqqb65751/themes/site/nir_pid4252/dist/images/rmb_logo_4c.png) ](https://www.rapidmicrobio.com/)\n\n## Investor Relations\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News & Events](/news-and-events/news-releases)\n    * [News Releases](/news-and-events/news-releases)\n    * [Events](/news-and-events/events)\n    * [Presentations](/news-and-events/presentations)\n  * [Stock Information](/stock-information/stock-quote-chart)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n  * [Corporate Governance](/corporate-governance/documents-and-charters)\n    * [Documents & Charters](/corporate-governance/documents-and-charters)\n    * [Board of Directors](/corporate-governance/board-of-directors)\n    * [Leadership](https://investors.rapidmicrobio.com/corporate-governance/management)\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Code of Business Conduct and Compliance Hotline](/code-business-conduct-and-ethics-0)\n  * [Financials & Filings](/financials-and-filings/sec-filings)\n    * [SEC Filings](/financials-and-filings/sec-filings)\n  * [IR Resources](/ir-resources/faqs)\n    * [FAQs](/ir-resources/faqs)\n    * [Email Alerts](/ir-resources/email-alerts)\n    * [Contact IR](/ir-resources/contact-ir)\n\n\n\n#  News Release Details \n\n## \n\nRapid Micro Biosystems to Announce Third Quarter 2024 Financial Results on November 1, 2024\n\n10/23/2024 \n\nLEXINGTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2024 financial results prior to the market open on Friday, November 1, 2024.\n\nIn conjunction with the release, the Company’s management team will host a webcast conference call beginning at 9:00 a.m. ET on Friday, November 1, 2024. The live audio webcast will be accessible on the Company’s website [here](https://www.globenewswire.com/Tracker?data=NPl4JC4U5ldfNC5obL7KeSVyxDT2Th16gB6C3WsOEJlcX9vR0relR5dz3pr-FepVFZFNqnK1t9oUL68YUFXdfSIDgSDz2bR7wOWZgt2J5kmr1ACYzr7HWzuz_ngdyhOt) and will be available for replay for one year from the webcast date.\n\n**About Rapid Micro Biosystems** Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual MQC testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands.\n\nFor more information, please visit [www.rapidmicrobio.com](https://www.globenewswire.com/Tracker?data=IJXeYarm-wQg7Xqdf4iDQU8VCxT645ff_d1XXbJeZcHsQbjLEoLQeiqYG6afPyDBfdUGbBdFvUqs8poCB2t70DpSwPI8_LQQ9r5wi4P7Mi0ISN5cpkyEZuhipRhZfPZh8Yi31uZ7cBQhcyLoN4hg_-QlAXPGBLGsXV_0FC8SO4e87zcWAVofxQdwnaNsGG5wcVMtWvRh6PFurWv1M0DHGbzHE0oFzZot3gTQaE0WQHaa_wXjxelK2jHZw6PtZtJz_Qi7ZwN5Cgcywn9ckflHMw==) or follow the Company on X (formerly known as Twitter) at [@rapidmicrobio](https://www.globenewswire.com/Tracker?data=aGyVSQ26Ytk21nELc49V3ib9KnnwLMIUdGZLON9vwWiHqsIh9OzdGmTt1ggxJ09cqxzLqa9TyPC7OCTSPiSgTBLcDfYVYEH5mwx8bGIzZF67hrcGRneigHX2JbPHZbvru9trMD0ULc1OoMwESRLgDPeqjRkP1nl9heKM_xTLmfxddO30f16FwSG30ZqfevF-w0kyQiPFJkyQmcwTOyxit3eCErsWwo1jiPymeBVjl_0i9n64niJ7cqeXVKfqjbPVPaMQUwI9-O8m1OiDoILpPXc0YPFz0OyO5Nc3pcYRoG9Z32HcPE4F9SRTXBwpXoJQdvsUHqaxKSfNIS89KRmAaDFhiBqiSq-aT7Pd7OI_GIFq2xdIU8HxfX67MrQuap_oVlNK6U-Wpcz1xoi_BPvf1mTm3pxubjrPqfnrwzw_4ttOUymgtObzfnDboAqdMWsFUaaHMUFeXtIxD3vZftEuLorPp9dbDQc5dvSj8vPNBSXYPiRLAbKxZpxTiuBbPG7cAg2awo6E6FyyyB4hhPBn3AAdaVojSwSgXykO9BY39CPysti930XOm-bu1kFV_8L6kvAYXCwKl_fTiF_iwluwvR6-JOJEaXCLqRZp5PWsm7_iE8D-p0ga5JPiDF-RdheYxY8i8MzYvEaPKklk5T1Gu3UPLiWlwP3bz41zl6ysPmyfNUf3E0XWhPQgtqTbdtAssGMCopE6tnRo9GRjnZwdQ4Gn2d7voOMBW2UP3COu1eE=) or on [LinkedIn](https://www.globenewswire.com/Tracker?data=yP8N0eo7ctdRFKwyr-YqKhYvrKXuzMnUvlpuQfPm7omD2Q_tKtKk9GSgzf_krkCw1VORfzZO_08tA4cZpAWEQpFRwLzlxy-Uzu-aMhDVv3So95TQSfLjCWBhocQx8r20FjZBd94cGr7O2FJPBAT9S7pYizZgTBhTjM7E2agf1f9xPQOyEGP-nXXuJ7-6FhLK0DV7Ei5ndupr4PqdDmviMPNs9fBe9Si_JV68rf2QPsSmCVPY_QILvjOZaYG6DAE-FD9VbyTw6zIKskjflmoOLNZkuQQ4dE2d6gErCKH05a9b3vvSkL483oRkId7ofjuwoeeQKa_E28b9fMarENzVgn_JO-VSRICwvo-EE2lFTY5EgR8CFy89C3JNFi7CJh_2kpED32ANPUzZ3z_DsLhlDp0eBOGwSJVihlTWqJku03Z0o7RSk7r3dIiX77tG_DHevVpUH_1PcvI6tbO1mr097VY5q1JUjVas7Ux_vQ5kqHTT8X-GORiQI30tsSSMZE7HqdIMl7XI2-GCCJzfyUT7S9pwYAb0E97ZQ47eAZ_ChwOe4r0B04hwvDwnn0eZtLLqL0Miz6Yz9X3Bo8c42UlNVoR3Di9lMO8Xb2SfcB6UzcBuqiy65waj4oN4xLLvyZzscLSBAlo3BlhcBJjDoorU1d73C2sRiaUTZRAb2tfD8ukU1h2l1yS9262UialzEH8GWrsW8d5uKxAkWft-EBTnT3PJp7iQtnM3AwvjyKspq910Wbbu1u6NZYsV8jVeRYro).\n\n![](https://ml.globenewswire.com/media/YTkxNjZkODktMDgyZS00NGRiLThiMTItNzhmNzhlMTVhZjBkLTEwMzAxMzQ=/tiny/Rapid-Micro-Biosystems-Inc-.png)\n\nInvestor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com\n\nRequest Email Alerts\n\n[](#)\n"
        }
      ]
    }
  ]
}